Sisram Medical Ltd. (HK:1696) has released an update.
Sisram Medical Ltd has announced the opening of a new direct office in Thailand, initiating operations with the injectable product Profhilo® after obtaining approval from the Thailand Food and Drug Administration. The company aims to enhance customer service, strengthen local market relationships, and increase brand awareness in the dynamic Southeast Asian economy. This strategic expansion is expected to drive long-term growth and shareholder returns by promoting a full portfolio in the wellness ecosystem.
For further insights into HK:1696 stock, check out TipRanks’ Stock Analysis page.